NCT03674138Completed
Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management alone. Scores on self-reported measures of depressive and anxiety symptoms along with quality of life will be compared between cohorts.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 99 (actual)
- First submitted
- 12 Sept 2018
- Start date
- 12 Sept 2018
- Primary completion date
- 3 Sept 2021
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Depression
- NCT number
- NCT03674138
What you commit to
- Study type: Interventional
- Participants enrolled: 99
- From 12 Sept 2018 to the primary completion date, 3 Sept 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients not diagnosed with cancer
- History of liver or allogenic stem cell transplant
- Patients with a known cognitive impairment (e.g., delirium, dementia, etc.) or psychological impairment (e.g., schizophrenia, bipolar disease, etc.) other than depressive and anxiety symptoms.
Other
- Antidepressant prescribing performed by a non-Moffitt psychiatrist after enrollment onto the clinical trial
- Known Pregnancy
Who the study is looking for
- Patients with a cancer diagnosis
- Be 18 years of age or older
- Patients who rate depression or anxiety \> 5 based on a 10 point scale
- Patients expected to live greater than 6 months
- Serum bilirubin and creatinine \< 1.5x upper limit of normal
- AST and ALT \< 3 times upper limit of normal
- Willing and able to provide written informed consent
- Able to complete self-assessment questionnaires
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| H Lee Moffitt Cancer Center and Research Institute Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.